Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study

Author:

Curtis Randall1ORCID,Wu Joanne2ORCID,Iorio Alfonso34ORCID,Frick Neil5,Nichol Michael2,Noone Declan6,O'Mahony Brian67ORCID,Page David8ORCID,Stonebraker Jeffrey9,Kucher Alexandra10,Clearfield Elizabeth11ORCID,Skinner Mark W.411ORCID,Germini Federico3412

Affiliation:

1. Factor VIII Computing Berkeley USA

2. Sol Price School of Public Policy University of Southern California Los Angeles USA

3. Department of Medicine McMaster University Hamilton ON Canada

4. Department of Clinical Epidemiology and Biostatistics McMaster University Hamilton ON Canada

5. National Hemophilia Foundation New York USA

6. Irish Haemophilia Society Dublin Ireland

7. Trinity College Dublin Dublin Ireland

8. Canadian Hemophilia Society Montreal Canada

9. Poole College of Management North Carolina State University Raleigh USA

10. Patient Outcomes Research Group Ltd Washington District of Columbia USA

11. Institute for Policy Development Ltd Washington District of Columbia USA

12. Clinical Epidemiology and Research Center (CERC) IRCCS Humanitas Research Hospital Milan Italy

Abstract

AbstractIntroductionThe Patient Reported Outcomes, Burdens, and Experiences (PROBE) questionnaire is a patient‐reported outcome tool that assesses quality of life and disease burden in people with haemophilia (PWH).AimTo assesses the test–retest reliability of PROBE when completed using the mobile phone application.MethodsWe recruited PWH, including carriers, and individuals with no bleeding disorders who attended haemophilia‐related workshops or via social media. Participants completed PROBE three times (twice on the app: T1 and T2, and once on the web, T3). Test–retest reliability was analysed for T1 versus T2 (app to app, time period one) and T2 versus T3 (app to web, time period two).ResultsWe enrolled 48 participants (median age = 56 [range 27–78] years). Eighteen participants (37.5%) were PWH and seven (14.6%) were carriers. On general health domain questions, we found almost perfect agreement, except for a question on the frequency of use of pain medication in the last 12 months [Kappa coefficient (κ) .72 and .37 for time period one and two, respectively] and any use of pain medications (κ .75) for time period two. For haemophilia‐related questions, we found substantial to perfect agreement, except for the questions on the number of joint bleeds in the previous 6 months for time period one (κ .49) and the number of bleeds in the previous two weeks for time period two (κ .34).ConclusionsThe results demonstrate the reliability of the PROBE app. The app can be used interchangeably with the paper and web platforms for PROBE administration.

Funder

Takeda Pharmaceutical Company

Swedish Orphan Biovitrum

Roche

Novo Nordisk

CSL Behring

Sanofi

Bayer

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3